HYDRAZINECARBOXIMIDAMIDE, 2,2'-(1-METHYL-1,2-ETHANEDIYLIDENE)BIS-, (E,E)-
Lymphoma, Non-Hodgkin
Small moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
411 Active assets in the Lymphoma, Non-Hodgkin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Memorial Sloan Kettering Cancer Center | Phase 3 | BBB |
PEGASPARGASE Ciusss de L'Est de l'Île de Montréal | Phase 4 | BBB |
Inno-206 National Cancer Institute (NCI) | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD | Phase 3 | BBB |
Entecavir Fudan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
HYDRAZINECARBOXIMIDAMIDE, 2,2'-(1-METHYL-1,2-ETHANEDIYLIDENE)BIS-, (E,E)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →